Table 2.
The mean, standard deviation, and range of the laboratory data in the case and control groups and p value of comparing these data between case and control groups.
| MAS | Control (active disease) | p value | |
|---|---|---|---|
| WBC1 (×103/uL) | 16122 ± 9105 (6100–38121) | 16280 ± 10857 (2520–61300) | 1 |
| WBC2 (×103/uL) | 8784 ± 10310 (520–38430) | 15679 ± 8502 (700–41200) | 0.001 |
| WBC3 (×103/uL) | 15617 ± 12602 (1130–46670) | 10299 ± 4551 (2140–25500) | 0.2 |
| PMN1 (×103/uL) | 11664 ± 8500 (1449–34080) | 11174 ± 7870 (1128–36556) | 0.4 |
| PMN2 (×103/uL) | 6775 ± 6569 (120–18069) | 11377 ± 7536 (583–35020) | 0.02 |
| PMN3 (×103/uL) | 11472 ± 9539 (1142–31408) | 5834 ± 3462 (1001–17110) | 0.07 |
| Lymph1 (×103/uL) | 4046 ± 4477 (866–19500) | 3815 ± 4441 (1108–32550) | 0.9 |
| Lymph2 (×103/uL) | 2638 ± 3731 (639–15333) | 3635 ± 1812 (1209–8694) | <0.001 |
| Lymph3 (×103/uL) | 3356 ± 2600 (550–8390) | 3501 ± 1917 (107–11272) | 0.4 |
| Hgb1 (g/dL) | 9.13 ± 1.45 (6.80–12.20) | 10.40 ± 1.40 (7.50–14.3) | 0.003 |
| Hgb2 (g/dL) | 7.96 ± 1.66 (6.10–11.4) | 10.33 ± 1.66 (7.30–14.5) | <0.001 |
| Hgb3 (g/dL) | 8.95 ± 1.16 (6.90–10.70) | 11.58 ± 1.91 (6.50–15) | <0.001 |
| PLT1 (/microliter) | 292588 ± 170526 (29000–638000) | 489365 ± 212249 (138000–1144000) | 0.001 |
| PLT2 (/microliter) | 105882 ± 91791 (9000–406000) | 502617 ± 189080 (56000–1010000) | <0.001 |
| PLT3 (/microliter) | 321785 ± 177361 (44000–770000) | 393512 ± 143221 (68000–779000) | 0.07 |
| ESR1 (mm/h) | 69.53 ± 40.96 (9–126) | 73.67 ± 30.24 (5–125) | 0.7 |
| ESR2 (mm/h) | 46.81 ± 49.47 (2–165) | 72.21 ± 35.82 (6–148) | 0.008 |
| ESR3 (mm/h) | 37.53 ± 30.176 (10–102) | 23.78 ± 27.85 (3–140) | 0.1 |
| CRP1 (mg/L) | 37 ± 23.61 (5–75) | 68 ± 52 (0–246) | 0.3 |
| CRP2 (mg/L) | 139 ± 101 (40–345) | 96 ± 70 (22–317) | 0.1 |
| CRP3 (mg/L) | 32.84 ± 46 (0.5–168) | 14.91 ± 19.4 (0–75) | 0.03 |
| ALT (u/L) | 315 ± 840 (12–3560) | 28.28 ± 31.4 (6–187) | <0.001 |
| AST (u/L) | 583 ± 1506 (17–6300) | 32.2 ± 21.7 (10–142) | <0.001 |
| ALP (u/L) | 409 ± 290 (165–1220) | 392 ± 171 (84–941) | 0.3 |
| ALB (gr/dL) | 3.03 ± 0.69 (2–4.3) | 3.80 ± 0.62 (2.7–4.7) | 0.002 |
| Total Pr (gr/dL) | 6.42 ± 1.77 (4–8.7) | 6.90 ± 1.04 (4.9–8.4) | 0.5 |
| BilT (mg/dL) | 5.36 ± 7.72 (0.4–24.3) | 0.88 ± 0.91 (0.4–2.7) | 0.050 |
| BilD (mg/dL) | 3.32 ± 4.87 (0.1–14) | 0.26 ± 0.16 (0.2–0.6) | 0.2 |
| Ferritin (ng/mL) | 60590 ± 73343 (1617–200000) | 5253 ± 5505 (300–18035) | 0.009 |
| Fibrinogen (mg/dL) | 517 ± 641 (130–4944) | 489 ± 94 (423–556) | 0.2 |
| LDH (Iu/L) | 1913 ± 1516 (136–4944) | 679 ± 336 (258–1318) | 0.02 |
| BUN (mg/dL) | 16.75 ± 11.94 (5–41) | 10.18 ± 4.03 (4–26) | 0.1 |
| Cr (mg/dL) | 0.60 ± 0.39 (0.12–1.80) | 0.55 ± 0.11 (0.3–0.8) | 0.5 |
| Na (meq/L) | 130 ± 6.3 (115–137) | 136 ± 4.3 (128–144) | 0.004 |
| TG (mg/dL) | 329 ± 188 (109–727) | 161 ± 119 (42–280) | 0.1 |
| Chol (mg/dL) | 224 ± 130 (112–530) | 181 ± 131 (88–274) | 0.7 |
| PT | 18.06 ± 7.7 (13–43) | 16.4 ± 7.9 (12–34) | 0.04 |
| PTT | 43 ± 14 (18–75) | 31.50 ± 9.44 (13–45) | 0.006 |
| INR | 1.67 ± 0.6 (1–2.7) | 1.16 ± 0.26 (1–1.8) | 0.009 |
MAS: Macrophage Activation Syndrome, WBC: white blood cells, PMN: polymorphonuclear, Lymph: lymphocytes, Hgb: hemoglobin, PLT: platelet, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ALP: alkaline phosphatase, ALB: albumin, Total Pr: total protein, Bil T: total bilirubin, Bil D: direct bilirubin, LDH: lactate dehydrogenase, BUN: blood urea nitrogen, Cr: creatinine, Na: natrium, TG: triglycerides, Chol: cholesterol, PT: prothrombin time, PTT: partial prothrombin time, and INR: international normalized ratio. The previous laboratory records: WBC1, PMN1, and so forth. The laboratory data at the onset of MAS (MAS group) or active rheumatologic disease (control group): WBC2, PMN2, and so forth. The laboratory data 1 month after discharge from the hospital: WBC3, PMN3, and so forth.